Research

Several RECOVER studies have reported on the symptoms of Long COVID. View studies [1], [2], [3], [4]. RECOVER research shows there are symptoms that cluster and present together. View studies [1], [2], [3]. In one study, researchers found six distinct symptom clusters. The clusters involve different body systems at the same time, including: the lungs; the brain and nervous system; and the heart and blood vessels. Some clusters include pain, and some are accompanied by abnormal laboratory findings. View the study. Another study found that four Long COVID symptom clusters (heart and lungs, neurological, gastrointestinal, and coexisting medical conditions) differed depending on the age of patients. In the study, children and teens were more likely to have gastrointestinal and upper respiratory problems such as stomachache and cough; adults aged 21-45 years were more likely to have neurological problems (such as brain fog and fatigue); and adults aged 66 and older were more likely to have coexisting medical conditions such as heart problems and diabetes. View the study.

Multisystem inflammatory syndrome in children (MIS-C) is a severe consequence of COVID-19 that is observed in some children. Using data from children hospitalized with MIS-C, RECOVER researchers found three clusters of symptoms. Cluster 1 included children with the highest number of organ systems affected and most severe symptoms—including exacerbated inflammation, low blood pressure, cardiac and pulmonary involvement, and kidney injury—with more common admission to the intensive care unit (ICU). Cluster 2 included children with fewer organ systems affected, moderate symptom presentation, and notable overlapping features with acute COVID-19. Lastly, Cluster 3 represented a mild presentation with the fewest organ systems involved. View the study.

RECOVER researchers are also examining how PASC diagnoses, underlying health conditions, and prescription medications might differ geographically. They compared electronic health records from four states (New York, Florida, Georgia, and Alabama) and found differences in the number of PASC conditions reported across data sites. Researchers found a wide range of diagnoses and medication categories that suggest differences in PASC diagnoses, conditions, and medications among different populations based on neighborhood socioeconomic status, age, gender, race, and outbreak waves. View the study.

Researchers found ethnic and racial differences in PASC symptoms and conditions in a RECOVER study of adults with COVID-19 in New York City between March 2020 and October 2021. In the period of 31–180 days after infection, compared to White people hospitalized for COVID-19, Black and Hispanic people hospitalized for COVID-19 had higher rates of certain PASC symptoms such as shortness of breath, chest pain and joint pain. They were also more likely to receive a new diagnosis of diabetes. The results also suggest that people from different racial and ethnic groups may experience different symptoms and conditions of PASC. View the study.

RECOVER researchers are trying to understand the prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in people with Long COVID. For this research, they asked 465 people with Long COVID about how often they experience Long COVID symptoms, ME/CFS symptoms, and post-exertional malaise (PEM) (worsening of symptoms after physical or mental activity). They found that over half (272/465, or 58%) of participants experienced ME/CFS. Further, those who experienced ME/CFS reported more severe symptoms (e.g., fatigue/extreme tiredness; feeling unrefreshed after waking in the morning; next day soreness or fatigue after nonstrenuous everyday activities; difficulty paying attention for long periods; and problems remembering things) compared to those who did not experience ME/CFS. The results also showed that participants experiencing ME/CFS had a 50% or greater reduction in their self-reported energy level based on a 7-point Likert scale, consistent with the case criteria. View the study.

RECOVER researchers are studying large groups of people over a long period of time to gain a deeper understanding of how long the symptoms last and whether it can have effects later in life. Learn more about RECOVER Longitudinal Observational Cohort Studies.

RECOVER researchers are studying whether Long COVID affects other diseases or health problems. They compared electronic health records (EHR) to examine possible links between Long COVID and new diagnoses of type 2 diabetes. The researchers analyzed data from patients who had at least one outpatient clinical visit during the periods 6 months before and 6 months after SARS-CoV-2 infection. The number of new diabetes diagnoses were 83% lower in the months after SARS-CoV-2 infection than in the period before infection. View the study.

In another study examining EHRs from 53 health systems in the US, researchers observed an association of acute kidney injury (AKI) with patients diagnosed with COVID-19. AKI was defined either by the increase of serum creatinine level or a diagnostic code. Researchers then characterized the incidence, geographic distribution, and temporal trends of AKI among patients hospitalized with COVID-19. Risk factors associated with AKI in these patients include older age, male sex, and Black and Asian races. Additionally, spikes in AKI cases in the US correlated with waves of COVID-19 in the last 2 years. Researchers also found that AKI was highly associated with mortality in patients with COVID-19, with more severe AKI being associated with a greater risk of death. View the study.

In another RECOVER study, researchers looked at the relationship between impaired cognition (cognitive concerns or dementia diagnosis) and death after SARS-CoV-2 infection in people with and without HIV. They studied 527 adults with laboratory-confirmed SARS-CoV-2 infection, including 64 people with HIV. People living with HIV had a higher prevalence of dementia (15.6% vs 6.0%) and cognitive concerns (21.9% vs 15.8%). People living with HIV also had a significantly increased risk of death from COVID-19 (17.2% vs. 6.3%). On average, people living with HIV and COVID-19 died at a younger age despite their HIV being under control of medication. View the study.

RECOVER studies are examining risk factors for developing Long COVID.

RECOVER researchers have found that SARS-CoV-2 infection increases the risk of developing post-acute sequelae of SARS-CoV-2 infection (PASC) and Long COVID. View studies [1], [2]. In another study, researchers found that 23% of people with SARS-CoV-2 infection developed PASC, while only 3.7% of people without a reported positive test developed symptoms consistent with PASC.

Researchers found that the risk of PASC increases with hospitalization for acute infection and similarly with reinfections. The study found that 39% of people hospitalized with acute COVID developed PASC, compared to 22% of people not hospitalized for acute COVID. Among people infected with the Omicron variant, those who had reinfections were more likely to develop PASC (21%) compared to those with one infection (16%). View the study.

RECOVER research using EHRs suggests that obstructive sleep apnea may increase the risk for developing Long COVID after infection. Among people who had COVID-19, adults with obstructive sleep apnea were more likely to experience long-term symptoms suggestive of Long COVID than those without the sleep disorder. The analysis of EHR found that adults with sleep apnea may have up to a 75% higher risk of developing Long COVID after infection. View the study.

RECOVER researchers found that certain environmental factors related to where people live, like air quality, access to food, green spaces, neighborhood characteristics, and social factors, may increase the risk of having Long COVID symptoms. View the study.

In another study, RECOVER researchers examined risk factors for developing PASC. They looked at EHR data from 31 health systems in the United States, comparing 8,325 individuals with PASC with 41,625 individuals with COVID. They matched data from patients within the same health system whose initial SARS-CoV-2 infections were within 45 days of one another to compare demographics and health conditions between those with and without a PASC diagnosis. Researchers found a higher likelihood of PASC diagnosis among individuals aged 40 to 69 years, female, with acute COVID-19, and living with other health conditions such as depression, chronic lung disease, and obesity. Researchers also found that in counties served by more doctors per capita, residents were more likely to receive a PASC diagnosis or care at a Long COVID clinic. Risk factors associated with a lower likelihood of developing PASC included younger age (18-29 years), male sex, non-Hispanic Black race, and comorbidities including psychosis, dementia, and tobacco smoking. View the study.

RECOVER researchers are studying whether variants of the SARS-CoV-2 virus and COVID-19 vaccines make a difference for developing Long COVID.

In a study following more than 9,000 people over time, RECOVER researchers found that PASC was more common and associated with more severe manifestations for adults infected before the Omicron variant emerged. View the study. Regardless of the variant, the rates of PASC among those fully vaccinated were lower than those who were unvaccinated. Researchers found the same pattern when they compared vaccinated and unvaccinated adults at three different points in time - in adults with post-acute COVID, pre-Omicron (31% vs. 37%), with acute Omicron infection (9.7 vs. 17%), and post-acute Omicron (16% vs. 22%). Similarly, in a large observational study, RECOVER researchers found that vaccination was consistently associated with lower rates of Long COVID, before and after Omicron emerged. View the study.

RECOVER researchers reviewed the electronic medical records (EHRs) of more than 15 million people (age 5 and older) to compare the risk of rare heart problems after a SARS-CoV-2 infection versus after being vaccinated for COVID-19. They found that the risk of having a rare heart problem after having COVID is much higher in people who did not receive a COVID vaccine than those who did. The risk of rare heart problems after COVID-19 vaccination with an mRNA vaccine (Pfizer or Moderna) was very low, supporting the continued use of vaccination to prevent COVID-19. View the study.

In children, vaccine effectiveness (VE) against Long COVID is less understood. Researchers studied the EHRs of children ages 5-17 that previously received the COVID-19 vaccine to examine VE in preventing Long COVID. After adjustment for important confounder factors to prevent bias, they found that within 12 months of vaccination, VE was 35.4% against probable (symptom-based) Long COVID and 41.7% against diagnosed (diagnosis code-based) Long COVID. Notably, VE was higher for adolescents aged 12-17 (50.3%) than for children aged 5-11 (23.8%). Overall, this research demonstrates that COVID vaccination has a moderate protective effect against Long COVID in children. View the study.

In addition to the observational cohort studies that re-examine participants over time, RECOVER researchers are conducting more than 40 different pathobiology studies focusing on COVID-19's effects on different body tissues and organs.

RECOVER researchers are studying Individuals with Long COVID who frequently report constant fatigue, PEM (symptoms worsening after physical or mental activity), and a variety of cognitive issues, like “brain fog.” RECOVER researchers examined 275 people with and without Long COVID to identify biological features associated with these symptoms. They found people with Long COVID had significant differences in their immune systems compared to those without Long COVID. In participants with Long COVID, researchers saw increases in counts of some immune cell types, while counts of other immune cells decreased. Researchers also saw higher antibody responses to SARS-COV2 and non-COVID viruses, particularly Epstein-Barr virus (a herpesvirus) in participants with Long COVID. Researchers suggest that persistent SARS-CoV-2 antigens, reactivation of herpes viruses, and chronic inflammation may contribute to Long COVID. View the study.

RECOVER researchers are studying the cells inside the nose that enable smell to understand why some people with COVID-19 experience a loss of their sense of smell, known as hyposmia. They examined 24 biopsies from 9 PASC patients with long-term smell loss after contracting COVID-19. Biopsies from people with their sense of smell intact served as a comparison. In participants with PASC, there was no trace of SARS-CoV-2 virus or its genetic material in olfactory epithelium. However, the cells supporting the protective barrier in the nose, known as sustentacular cells, showed signs of reacting to ongoing inflammation. This reaction was also linked to a decrease in the number of olfactory sensory nerve cells (neurons). These findings suggest that inflammation (mediated by T-cells) continues in the olfactory epithelium even after the virus has been eliminated from the tissue. This is a potential explanation for the persistent loss of smell experienced by some people living with Long COVID. View the study.

Inflammation caused by infections can have a lasting impact on certain types of cells in the human body, including those related to the immune system. In one study, researchers sought to uncover how inflammation could impact a specific cell type—hematopoietic stem and progenitor cells (HSPC)—which are crucial for the formation of blood and immune cells. Researchers found that the cells of individuals who had a serious case of COVID-19 could retain changes for several months to a year after infection. They saw changes in both the physical traits of the cells and their genetic programming. They also linked these changes to proteins that control gene expression, changes in the regulation of inflammatory processes, and a lasting increase in the production of certain immune cells. Importantly, the observed changes in HSPC were passed to their “offspring” as they developed into mature immune cells. Finally, researchers found that a molecule called IL-6 played a role in maintaining these lasting effects in human COVID-19 patients as well as in the study model for SARS-CoV-2 infection performed in mice. Overall, researchers suggest changes to HSPC at the genetic level could be responsible for changes in the immune system after infection, especially in people who experienced severe COVID-19. View the study.

At this time, the only known way to prevent Long COVID is to avoid getting COVID-19. The observational cohort studies and the RECOVER Pathobiology Research Program are investigating potential mechanisms for how some people may be protected from Long COVID or some of its symptoms.

RECOVER researchers are making progress toward understanding why some people develop Long COVID and how these long-term symptoms affect one’s health. Based on what the researchers have learned so far, RECOVER has launched clinical trials to test different interventions for Long COVID. The eight clinical trials under the RECOVER Initiative will explore 13 study interventions, or possible treatments, for post-acute sequelae of SARS-CoV-2 infection (PASC), known as Long COVID.

There are 5 RECOVER platform protocols with one or more clinical trials within the platform. The protocol for each platform describes the goals of the research, who can enroll, possible treatments, study activities, and more. The five platforms are:

• RECOVER-NEURO focuses on treatments for cognitive symptoms associated with Long COVID.
• RECOVER-VITAL focuses on treating viral persistence and reactivation, which is when the SARS-CoV-2 virus stays in the body and damages organs or the immune system. The latter has been considered as a possible cause for Long COVID. This trial focuses on treatments to stop the virus from replication to prevent continued damage and to resolve symptoms caused by the virus.
• RECOVER-AUTONOMIC focuses on treatments for adults who have an autonomic nervous system disorder, called Postural Orthostatic Tachycardia Syndrome (POTS), a common consequence of Long COVID.
• RECOVER-SLEEP focuses on treatments for sleep disturbances and hypersomnia (trouble staying awake during the day).
• RECOVER-ENERGIZE focuses on treatments for exercise intolerance and the worsening of symptoms following physical or mental exertion known as PEM in patients with Long COVID.

More information about RECOVER clinical trials can be found at trials.recoverCOVID.org.

One RECOVER study identified seven patients with mild Multisystem Inflammatory Syndrome in Children (MIS-C) and evaluated the option to manage them in outpatient setting without treatments focused on the immune system (called immunomodulators). MIS-C is a multi-organ inflammatory condition of Long COVID that mainly affects children and young adults. The result from this small study suggested that outpatient management alone may be effective at preventing hospitalization for patients with mild MIS-C. View the study.